

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1625JXC

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1	Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3 OCT 19	BEILSTEIN updated with new compounds
NEWS 4 NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5 NOV 19	WPIX enhanced with XML display format
NEWS 6 NOV 30	ICSD reloaded with enhancements
NEWS 7 DEC 04	LINPADOcdb now available on STN
NEWS 8 DEC 14	BEILSTEIN pricing structure to change
NEWS 9 DEC 17	USPATOLD added to additional database clusters
NEWS 10 DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11 DEC 17	DGENE now includes more than 10 million sequences
NEWS 12 DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13 DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14 DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15 DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16 JAN 02	STN pricing information for 2008 now available
NEWS 17 JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18 JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19 JAN 28	MARPAT searching enhanced
NEWS 20 JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21 JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22 JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23 FEB 08	STN Express, Version 8.3, now available
NEWS 24 FEB 20	PCI now available as a replacement to DPCI
NEWS 25 FEB 25	IFIREF reloaded with enhancements
NEWS 26 FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27 FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:38:51 ON 27 MAR 2008

FILE 'REGISTRY' ENTERED AT 12:39:02 ON 27 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAR 2008 HIGHEST RN 1010293-80-7
DICTIONARY FILE UPDATES: 26 MAR 2008 HIGHEST RN 1010293-80-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s atorvastatin?
L1 15 ATORVASTATIN?

=> s 11 and ?amorph?
LEFT TRUNCATION IGNORED FOR FILE 'REGISTRY'
420 AMORPH?

L2 0 L1 AND ?AMORPH?
Left truncation is not valid in the specified search field in the
specified file. The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID'.


If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> s 11 and amorphous
17 AMORPHOUS
L3 0 L1 AND AMORPHOUS

=> d 11 1-15

L1 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 915092-86-3 REGISTRY
ED Entered STN: 10 Dec 2006
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, phenylmethyl ester, (β R, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN Atorvastatin benzyl ester
FS STEREOSEARCH
MF C40 H41 F N2 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 915092-85-2 REGISTRY
ED Entered STN: 10 Dec 2006
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-propenyl ester, (β R, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN Atorvastatin allyl ester
FS STEREOSEARCH
MF C36 H39 F N2 O5
SR CA
LC STN Files: CA, CAPLUS


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 874114-41-7 REGISTRY
ED Entered STN: 13 Feb 2006
CN Magnesium, bis[$(\beta$ R, δ R)-2-(4-fluorophenyl)- β -(hydroxy- κ O)- δ -hydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoato- κ O1]-, (T-4)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Magnesium Atorvastatin
DR 928371-13-5, 956035-12-4, 947698-59-1
MF C66 H68 F2 Mg N4 O10
CI CCS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 844874-19-7 REGISTRY
ED Entered STN: 10 Mar 2005
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, bismuth(3+) salt (3:1), (β R, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN Tris(atorvastatin) bismuth
FS STEREOSEARCH
MF C33 H35 F N2 O5 . 1/3 Bi
SR CA
LC STN Files: CA, CAPLUS, CASREACT
CRN (134523-00-5)

Absolute stereochemistry.




● 1/3 Bi(III)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 501121-34-2 REGISTRY
ED Entered STN: 01 Apr 2003
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (β S, δ S)- (CA INDEX NAME)
OTHER NAMES:
CN 3S,5S-Atorvastatin
FS STEREOSEARCH
MF C33 H35 F N2 O5
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 344423-98-9 REGISTRY
ED Entered STN: 03 Jul 2001
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, trihydrate, (β R, δ R)- (9CI)
OTHER NAMES:
CN Atorvastatin hemicalcium sesquihydrate
CN Atorvastatin hemicalcium trihydrate
FS STEREOSEARCH
MF C33 H35 F N2 O5 . 1/2 Ca . 3/2 H2 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, MRCK*, PATDPASPC, TOXCENTER, USPAT2, USPATFULL
(*file contains numerically searchable property data)
CRN (134523-00-5)

Absolute stereochemistry.




● 1/2 Ca

● 3/2 H2O

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 340266-37-7 REGISTRY
ED Entered STN: 11 Jun 2001
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monoammonium salt, (β R, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN Atorvastatin ammonium salt
FS STEREOSEARCH
MF C33 H35 F N2 O5 . H3 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (134523-00-5)

Absolute stereochemistry.




● NH3

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 214217-88-6 REGISTRY
ED Entered STN: 12 Nov 1998
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-4-[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (β R, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN RMS 241423-01
CN p-Hydroxyatorvastatin
CN PD 142842
FS STEREOSEARCH
MF C33 H35 F N2 O6
CI COM
SR CA
LC STN Files: ANABSTR, CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
23 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 214217-86-4 REGISTRY
ED Entered STN: 12 Nov 1998
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-4-[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (BR, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN BMS 243887-01
CN o-Hydroxavatorvastatin
CN PD 152873
FS STEREOSEARCH
MF C33 H35 F N2 O6
CI COM
SR CA
LC STN Files: ANABSTR, BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

33 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 134523-03-8 REGISTRY
ED Entered STN: 28 Jun 1991
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (BR, δ R)- (CA INDEX NAME)
OTHER NAMES:
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), [R-(R*,R*)]-
OTHER NAMES:
CN Atorvastatin calcium
CN Atorvastatin hemicalcium
CN Atorvastatin hemicalcium salt
CN CI 981
CN Lipitor
CN Sortis
CN Tabor
CN YM 548
FS STEREOSEARCH
DR 334757-04-9
MF C33 H35 F N2 O5 . 1/2 Ca
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUG, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPAFC, PHAR, PIRA, PRMT, PROUDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (134523-00-5)

Absolute stereochemistry.




● 1/2 Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

433 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
436 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 134523-02-7 REGISTRY
ED Entered STN: 28 Jun 1991
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, potassium salt (1:1), (BR, δ R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monopotassium salt, [R-(R*,R*)]
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monopotassium salt, (BR, δ R)- (SC1)
OTHER NAMES:
CN Atorvastatin potassium
FS STEREOSEARCH
MF C33 H35 F N2 O5 . K
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPAT2, USPATFULL
CRN (134523-00-5)

Absolute stereochemistry.




● K

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 134523-01-6 REGISTRY
ED Entered STN: 28 Jun 1991
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, sodium salt (1:1), (BR, δ R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monosodium salt, [R-(R*,R*)]
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monosodium salt, (BR, δ R)- (9CI)
OTHER NAMES:
CN Atorvastatin sodium
FS STEREOSEARCH
MF C33 H35 F N2 O5 . Na
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, IMSPATENTS, IMSRESEARCH, MRCK*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (134523-00-5)

Absolute stereochemistry.




● Na

34 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
34 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 134523-00-5 REGISTRY
ED Entered STN: 28 Jun 1991
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (β R, δ R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, [R-(R*,R*)]- OTHER NAMES:
CN 2-(p-Fluorophenyl)- β , δ -dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
CN (3R, 5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl]pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
CN Atorvastatin
CN Atorvastatin acid
CN Cardy1
FS STEREOSEARCH
MF C33 H35 F N2 O5
CI COM
SR CR
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABESTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUG, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDFAASC, PRCMT, ProusDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3252 REFERENCES IN FILE CA (1907 TO DATE)
76 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3288 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 125995-03-1 REGISTRY
ED Entered STN: 23 Mar 1990
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-, (2R-tetrahydron)-
OTHER NAMES:
CN 5-(4-Fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-exotetrahydropyran-2-yl]ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
CN Atorvastatin 8-lactone
CN Atorvastatin lactone
FS STEREOSEARCH
DR 142062-65-5
MF C33 H33 F N2 O4
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, MRCK*, PS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

77 REFERENCES IN FILE CA (1907 TO DATE)
77 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN
RN 134395-00-9 REGISTRY
ED Entered STN: 21 Jun 1991
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, (β R, δ R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, [R-(R*,R*)]- OTHER NAMES:
CN (3R, 5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl]pyrrol-1-yl]-3,5-dihydroxyheptanoic acid tert-butyl ester
CN Atorvastatin tert-butyl ester
FS STEREOSEARCH
MF C37 H43 F N2 O5
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, PS, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

26 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	46.83	47.04

FILE 'CAPLUS' ENTERED AT 12:40:34 ON 27 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2008 VOL 148 ISS 13
FILE LAST UPDATED: 26 Mar 2008 (20080326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007492770 CAPLUS
 DOCUMENT NUMBER: 147413032
 TITLE: Process for manufacturing amorphous atorvastatin calcium
 INVENTOR(S): Vakil, Manish H.; Purohit, Parva Y.; Kumar, Sharma Rajiv; Kumar, Agarwal Virendra
 PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
 SOURCE: Indian Pat. Appl., 22pp.
 CODEN: INXXBQ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2004MU00758	A	20070427	IN 2004-MU758	20040716
PRIORITY APPLN. INFO.:			IN 2004-MU758	20040716

AB The present invention relates to convenient preparation of amorphous atorvastatin calcium by spray drying the solution of atorvastatin calcium in comprising hydroxylic solvent system on the other solvent system that has got higher evaporation rate.
 IT 134523-03-8P, Atorvastatin calcium
 RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (process for manufacturing amorphous atorvastatin calcium)
 RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.




●1/2 Ca

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 915092-85-2 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-propen-1-yl ester, (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915092-86-3 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, phenylmethyl ester, (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 134523-03-8P, Atorvastatin calcium
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (process for the production of amorphous atorvastatin calcium)
 RN 134523-03-8 CAPLUS

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20061176938 CAPLUS
 DOCUMENT NUMBER: 145505324
 TITLE: A process for the production of amorphous atorvastatin calcium
 INVENTOR(S): Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Srinivasulu, Gudipati; Srinivas, Katakam
 PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Limited, India
 SOURCE: Indian, 16pp.
 CODEN: INXXAP
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 193427	A1	20040717	IN 2001-MA949	20011122
PRIORITY APPLN. INFO.:			IN 2001-MA949	20011122

OTHER SOURCE(S): CASREACT 145:505324
 AB A process for the production of amorphous atorvastatin calcium comprises: (A) heating a mixture of [R-(β^* , δ^*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid alkyl ester (e.g., tert-Bu ester), allyl ester, or benzyl ester with a nitrile (e.g., acetonitrile) and an alkali (e.g., sodium hydroxide) to about 25-50° C , maintaining the reaction mixture of step (A) at 25-50° C for about 3-9 h; (B) adding to the step (B) reaction mixture an aqueous solution of a calcium salt (e.g., calcium acetate hemihydrate); (D) further stirring the reaction mixture at 30-50° C for about 30 min to 2 h; (E) filtering the reaction solution obtained in step (D); (F) distilling the solvent from the reaction solution of step (E) to yield a residue; (G) dissolving the residue of step (F) in non-hydroxylic polar solvent (e.g., MIBK); (H) distilling the solvent of step (G) and subsequently adding a non-polar hydrocarbon solvent (e.g., cyclohexane); and (I) isolating the obtained amorphous Atorvastatin calcium by filtration or other known methods.
 IT 134395-00-9, Atorvastatin tert-butyl ester 915092-85-2, Atorvastatin allyl ester 915092-86-3, Atorvastatin benzyl ester
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (in a process for the production of amorphous atorvastatin calcium)
 RN 134395-00-9 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)


Absolute stereochemistry.



●1/2 Ca

RN 915092-86-3 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, phenylmethyl ester, (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 134523-03-8P, Atorvastatin calcium
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (process for the production of amorphous atorvastatin calcium)
 RN 134523-03-8 CAPLUS


L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006411701 CAPLUS
 DOCUMENT NUMBER: 144:419647
 TITLE: Process for forming amorphous atorvastatin
 INVENTOR(S): Debettencourt, Antone John, III; Rose, Peter Robert; Shalaev, Evgenyi Yur'evich; Quallich, George Joseph; Ziegler, Carl Bernard
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046109	A1	20060504	WO 2005-IB3173	20051012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LZ, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GG, KE, LS, MW, MZ, NA, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RO, TJ, TM				
AU 2005298383	A1	20060504	AU 2005-298383	20051012
CA 2585836	A1	20060504	CA 2005-2585836	20051012
EP 1807055	A1	20070718	EP 2005-796593	20051012
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LZ, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101045141	A	20070503	CN 2005-80037285	20051012
IN 2007DN02889	A	20070817	IN 2007-DN2889	20070418
MX 200704722	A	20070615	MX 2007-4722	20070419
KR 2007067175	A	20070627	KR 2007-709632	20070427
PRIORITY APPLN. INFO.:			US 2004-623086P	P 20040428
		WO 2005-IB3173	W 20051012	

AB A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxyl solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalinizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin. Amorphous atorvastatin calcium was obtained by freeze-drying from a solution of DMSO.
 IT 134523-00-5P, Atorvastatin 134523-03-8P, Atorvastatin
 RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (process for forming amorphous atorvastatin)
 RN 134523-00-5 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (β R, δ R)-


L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20051154524 CAPLUS
 DOCUMENT NUMBER: 143:410962
 TITLE: Process for forming amorphous atorvastatin calcium
 INVENTOR(S): Rose, Peter Robert; Leonard, Jason Albert
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100313	A1	20051027	WO 2005-IB804	20050404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, RG, RZ, MD, RO, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LZ, LU, MC, NL, PL, PT, RO, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005232959	A1	20051027	AU 2005-232959	20050404
CA 2562844	A1	20051027	CA 2005-2562844	20050404
EP 1742910	A1	20070117	EP 2005-718356	20050404
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LZ, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1960972	A	20070509	CN 2005-80017687	20050404
BR 2005009923	A	20070918	BR 2005-9923	20050404
JP 2007532622	T	20071115	JP 2007-507860	20050404
US 2007225353	A1	20070927	US 2006-578084	20061012
MX 2006PA11987	A	20070116	MX 2006-PA11987	20061016
IN 2006DN06030	A	20070427	IN 2006-DN6030	20061016
NO 2006005229	A	20061114	NO 2006-5229	20061114
PRIORITY APPLN. INFO.:		US 2004-562948P	P 20040416	
		WO 2005-IB884	W 20050404	

AB Forming amorphous atorvastatin calcium comprises the steps of dissolving atorvastatin calcium in a solvent to form a solution, followed by adding the solution to a mixture comprising a non-solvent and a hydroxyl solvent to afford amorphous atorvastatin.
 IT 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYR (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (process for forming amorphous atorvastatin calcium)
 RN 134523-00-5 CAPLUS


L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20041036720 CAPLUS
 DOCUMENT NUMBER: 142:28246
 TITLE: Process for preparation of amorphous atorvastatin calcium
 INVENTOR(S): Sebastian, Sonny; Devarasetty, Sitaramaiah; Dandala, Ramesh; Sivakumaran, Meenakshisunderam
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 13 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242670	A1	20041202	US 2004-858261	20040601
PRIORITY APPLN. INFO.:			IN 2003-MA438	A 20030602

AB Process for the preparation of amorphous form of atorvastatin calcium from crystalline atorvastatin calcium or from a mixture of crystalline and amorphous atorvastatin calcium by spray drying or by pulverization method is described. For example, 15 g of crystalline atorvastatin calcium dissolved in 100 mL of methanol were spray dried at

a temperature of 58° to 62° using nitrogen as drying gas until a white amorphous powder of atorvastatin calcium was obtained. The amorphous material thus obtained was dried under reduced pressure till

LOD 0.5%, having residual solvent level of 0.015% for methanol. Purity of amorphous atorvastatin calcium obtained was 98.7%.

IT 134523-03-8, Atorvastatin calcium
 RL: PEP (Physical, engineering or chemical process); PVP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(preparation of amorphous atorvastatin calcium by spray drying or pulverization method)

RN 134523-03-8 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●1/2 Ca

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004878372 CAPLUS
 DOCUMENT NUMBER: 141:337649
 TITLE: Process for the preparation of amorphous calcium salt of atorvastatin
 INVENTOR(S): Antoncic, Ljubomir; Sorsak, Gorazd; Copar, Anton
 PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia
 SOURCE: PCT Int. Appl., 30 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089895	A1	20041021	WO 2004-SI13	20040409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: BW, CR, DE, DK, ES, FR, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, BY, KG, KE, LS, MM, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21461	A	20041031	SI 2003-100	20030411
SI 21505	A	20041231	SI 2003-138	20030606
AU 2004228607	A1	20041021	AU 2004-228607	20040409
CA 2520740	A1	20041021	CA 2004-2520740	20040409
EP 1615884	A1	20060118	EP 2004-726842	20040409
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HO, PL, SK, HR				
BR 2004009292	A	20060411	BR 2004-9292	20040409
US 2006287538	A1	20061221	US 2005-552562	20051011
PRIORITY APPLN. INFO.:			SI 2003-100	A 20030411
			SI 2003-138	A 20030606
			WO 2004-SI19	A 20040409

OTHER SOURCE(S): MARPAT 141:337649

AB Present invention refers to the process of preparing amorphous atorvastatin calcium without intermediate isolation of crystal or undefined mixture of crystal and amorphous atorvastatin calcium, resp. Forming of calcium atorvastatin salt is carried out in a mixture of chlorinated organic solvent or cyclic hydrocarbon solvent, resp., the non-hydroxyl organic solvent, and water, the source of calcium ions is calcium acetate or calcium chloride, resp. Atorvastatin calcium was prepared by the reaction of atorvastatin in THF with aqueous solution of calcium acetate monohydrate which was then separated and dried.

IT 134523-00-5, Atorvastatin


RL: RCT (Reactant); RACT (Reactant or reagent)

(process for preparation of amorphous calcium salt of atorvastatin)

RN 134523-00-5 CAPLUS

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 134523-03-8, Atorvastatin calcium


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(process for preparation of amorphous calcium salt of atorvastatin)

RN 134523-03-8 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:555459 CAPLUS
 DOCUMENT NUMBER: 137:114534
 TITLE: Atorvastatin calcium crystal forms
 INVENTOR(S): Joy, Mathew; Ganesh, Sambasivam
 PATENT ASSIGNEE(S): Biocon India Limited, India
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057228	A1	20020725	WO 2001-1N4	20010117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
AU 2001234057	A1	20020730	AU 2001-234057	20010117
PRIORITY APPLN. INFO.:			WO 2001-1N4	W 20010117

AB A process for the preparation of amorphous atorvastatin calcium and its hydrates thereof comprise: (a) dissolving heterogeneous mixture of atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-hydroxylic solvent or adding the dissolved atorvastatin to the non-hydroxylic solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.
 IT 134523-03-8, Atorvastatin hemicalcium salt
 RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); FVP (Physical process); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process); USES (Uses)
 (atorvastatin calcium crystal forms)
 RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 2000:841975 CAPLUS
 DOCUMENT NUMBER: 134:21435
 TITLE: Process for the production of amorphous atorvastatin calcium
 INVENTOR(S): Kumar, Yatendra; Thaper, Rajesh Kumar; Kumar, S. M. Dileep
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071116	A1	20001130	WO 2000-IB14	20000106
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ				
FW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 191236	A1	20031011	IN 1999-DE775	19990525
EP 1185264	A1	20020313	EP 2000-900300	20000106
EP 1185264	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
BR 2000010923	A	20020716	BR 2000-10923	20000106
AU 778962	B2	20041223	AU 2000-19367	20000106
CN 1680315	A	20051012	CN 2005-1005283	20000106
AT 362759	T	20070615	AT 2000-900300	20000106
ES 2284472	T3	20071116	ES 2000-900300	20000106
ZA 2001009656	A	20020627	ZA 2001-9656	20011123
US 6528660	B1	20030304	US 2002-979475	20020212
US 2003149279	A1	20030807	US 2003-378574	20030303
PRIORITY APPLN. INFO.:		IN 1999-DE775	A 19990525	
		CH 2000-808027	A3 20000106	
		WO 2000-IB14	W 20000106	
		US 2002-979475	A1 20020212	

AB A process for the preparation of amorphous atorvastatin calcium and hydrates comprises: (a) dissolving crystalline atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-polar hydrocarbon anti-solvent or adding the dissolved atorvastatin to the non-polar anti-solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.
 IT 134523-03-8, Atorvastatin calcium
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(process for the prodn. of amorphous atorvastatin calcium)
 RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997204226 CAPLUS
 DOCUMENT NUMBER: 126199450
 TITLE: Preparation of atorvastatin in an amorphous form
 INVENTOR(S): Lin, Min; Schweiss, Dieter
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Lin, Min; Schweiss,
 Dieter
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703960	A1	19970206	WO 1996-US11807	19960716
W: AU, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RN: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
HR 960312	B1	20011031	HR 1996-312	19960703
CA 2220455	A1	19970206	CA 1996-2220455	19960716
CA 2220455	C	20020924		
AU 9664978	A	19970213	AU 1996-64978	19960716
AU 700794	B2	19990114		
EP 839132	A1	19980506	EP 1996-924553	19960716
EP 839132	B1	20010307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, SE, SI, LT, LV, FI				
CN 11930356	A	19980819	CN 1996-195631	19960716
CN 1087269	B	20020710		
BR 9609714	A	19990223	BR 1996-9714	19960716
IL 122161	A	19990714	IL 1996-122161	19960716
JP 11510486	T	19990914	JP 1997-506814	19960716
JD 4064459	B2	20080319		
NZ 313008	A	20000128	NZ 1996-313008	19960716
IN 185276	A1	200001216	IN 1996-DE1579	19960716
HU 9903017	A3	20010129	HU 1999-3017	19960716
HU 220343	B	20011228		
AT 199542	T	20010315	AT 1996-924553	19960716
ES 2156997	T3	20010801	ES 1996-924553	19960716
C2 289421	B6	20020116	CZ 1998-122	19960716
EE 3605	B1	20020215	EE 1997-369	19960716
SR 283204	B6	20030304	SK 1998-58	19960716
RO 120069	B1	20050830	RO 1998-60	19960716
PL 191017	B1	20060331	PL 1996-324463	19960716
ZA 9606043	A	19970203	ZA 1996-6043	19960717
BG 63631	B1	20020731	BG 1998-102188	19980114
US 6087511	A	20000711	US 1998-983369	19980115
NO 9800209	A	19980116	NO 1998-209	19980116
NO 309322	B1	20010115		
HK 1018054	A1	20021101	HK 1998-113382	19981215
US 6274740	B1	20010814	US 2000-657469	20000907
GR 3035859	T3	20010831	GR 2001-400710	20010515
PRIORITY APPLN. INFO.:			US 1995-1453P	P 19950717
		WO 1996-US11807		W 19960716

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 US 1998-983369 A1 19980115


US 1999-453189 B1 19991202

AB The title process comprises dissolving crystalline Form I atorvastatin in a non-hydroxyl solvent and removal of the solvent to give amorphous atorvastatin.

IT 134523-03-8P
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of atorvastatin in an amorphous form)

RN 134523-03-8 CAPLUS
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino]carbonyl-, calcium salt (2:1), (β R, δ R)- (CA INDEX NAME)

Absolute stereochemistry.




• 1/2 Ca

IT 125995-03-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of atorvastatin in an amorphous form)

RN 125995-03-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

57.81 104.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-7.20 -7.20

STN INTERNATIONAL LOGOFF AT 12:43:39 ON 27 MAR 2008